Sharp Therapeutics Corp. ( (TSE:SHRX) ) has shared an announcement.
Sharp Therapeutics Corp. has announced that STX Partners LLP and Newlin Investment Company have exercised their common share purchase warrants, resulting in aggregate gross proceeds of US$2.5 million for the company. This investment is expected to accelerate Sharp’s progress towards clinical trials for its lead programs, reinforcing the company’s strategy to increase value and release key clinical data. The move demonstrates ongoing support from major stakeholders, positioning Sharp to advance its goal of becoming a global therapeutics company.
More about Sharp Therapeutics Corp.
Sharp Therapeutics Corp. is a pre-clinical-stage biotechnology company focused on developing small molecule therapies for hereditary disorders. The company utilizes a discovery platform that combines high throughput screening technologies with computationally optimized compound libraries to address cellular trafficking defects and allosteric protein activation, aiming to treat genetic disorders with conventional pill-based medicines.
YTD Price Performance: -27.27%
Average Trading Volume: 3,445
For an in-depth examination of SHRX stock, go to TipRanks’ Stock Analysis page.